TY - JOUR
T1 - A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics
AU - Wu, Rongling
AU - Tong, Chunfa
AU - Wang, Zhong
AU - Mauger, David
AU - Tantisira, Kelan
AU - Szefler, Stanley J.
AU - Chinchilli, Vernon M.
AU - Israel, Elliot
PY - 2011/10
Y1 - 2011/10
N2 - Genome-wide association studies (GWAS) have emerged as a powerful tool to identify loci that affect drug response or susceptibility to adverse drug reactions. However, current GWAS based on a simple analysis of associations between genotype and phenotype ignores the biochemical reactions of drug response, thus limiting the scope of inference about its genetic architecture. To facilitate the inference of GWAS in pharmacogenomics, we sought to undertake the mathematical integration of the pharmacodynamic (PD) process of drug reactions through computational models. By estimating and testing the genetic control of PD and pharmacokinetic (PK) parameters, this mechanistic approach does not only enhance the biological and clinical relevance of significant genetic associations, but also improve the statistical power and robustness of gene detection. This report discusses the general principle and development of PDs-based GWAS, highlights the practical use of this approach in addressing various pharmacogenomic problems, and suggests that this approach will be an important method to study the genetic architecture of drug responses or reactions.
AB - Genome-wide association studies (GWAS) have emerged as a powerful tool to identify loci that affect drug response or susceptibility to adverse drug reactions. However, current GWAS based on a simple analysis of associations between genotype and phenotype ignores the biochemical reactions of drug response, thus limiting the scope of inference about its genetic architecture. To facilitate the inference of GWAS in pharmacogenomics, we sought to undertake the mathematical integration of the pharmacodynamic (PD) process of drug reactions through computational models. By estimating and testing the genetic control of PD and pharmacokinetic (PK) parameters, this mechanistic approach does not only enhance the biological and clinical relevance of significant genetic associations, but also improve the statistical power and robustness of gene detection. This report discusses the general principle and development of PDs-based GWAS, highlights the practical use of this approach in addressing various pharmacogenomic problems, and suggests that this approach will be an important method to study the genetic architecture of drug responses or reactions.
UR - http://www.scopus.com/inward/record.url?scp=80053936671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053936671&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2011.09.001
DO - 10.1016/j.drudis.2011.09.001
M3 - Review article
C2 - 21920452
AN - SCOPUS:80053936671
SN - 1359-6446
VL - 16
SP - 884
EP - 890
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 19-20
ER -